One question that needs more attention is why are gay men and lesbians excluded from participating in certain medical studies? A little over a year ago a letter written by three scientists from the Fox Chase Cancer Center in Philadelphia appeared in The New England Journal of Medicine. The letter cited several dozen clinical trials [...]
One of the common side effects reported from chemotherapy with Taxotere is neuropathy. In the trial used to receive FDA approval, TAX 327 which had 332 patients. In that trial the following percentage of men reported incidents of neuropathy: Neuropathy Sensory- Nerve damage causing tingling or pain, usually in feet or hands: Any Grade- 30.4% [...]
The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California. Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference. [...]
The use of the PSA as a prostate cancer screening tool has been a controversial issue for many years. Within the last year the issue has again come to the forefront of the public awareness, especially because of the recent move of the U.S Preventative Task Force to discourage using the PSA as a screening [...]
Researchers at Ohio State University report that they have developed a new mathematical model for men with advanced prostate cancer who are on androgen deprivation therapy (ADT). This model could guide future treatment decisions for men with advanced prostate cancer, specifically, helping to decide which men would benefit from ADT on an intermittent schedule (IADT). [...]